Tim van Hauwermeiren
Fondateur chez ARGENX SE
Fortune : 34 M $ au 30/04/2024
Profil
Fondateur d'argenx SE, Tim van Hauwermeiren occupe actuellement le poste de président d'Aelin Therapeutics NV et de directeur général et directeur exécutif d'argenx SE. Il est également membre du conseil d'administration d'iTeos Therapeutics SA et d'iTeos Therapeutics, Inc. Dans le passé, il a occupé le poste de chef de groupe chez Procter & Gamble Co. et celui de Senior Manager-Business Development chez Ablynx NV. Il a obtenu un MBA à la Vlerick Leuven Gent Management School ainsi qu'un diplôme d'études supérieures et un diplôme de premier cycle à l'université de Gand.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARGEN-X SE
0,12% | 20/02/2024 | 71 986 ( 0,12% ) | 27 M $ | 30/04/2024 |
ARGENX SE ADR
0,03% | 31/08/2023 | 18 100 ( 0,03% ) | 7 M $ | 30/04/2024 |
ITEOS THERAPEUTICS, INC.
-.--% | 16/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Tim van Hauwermeiren
| Sociétés | Poste | Début |
|---|---|---|
| ARGENX SE | Fondateur | 01/01/2008 |
| ITEOS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/06/2018 |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Directeur/Membre du Conseil | 27/06/2018 |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Président | - |
Anciens postes connus de Tim van Hauwermeiren
| Sociétés | Poste | Fin |
|---|---|---|
| RAYZEBIO, INC. | Directeur/Membre du Conseil | 26/02/2024 |
| ABLYNX | Corporate Officer/Principal | - |
| PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Formation de Tim van Hauwermeiren
| Vlerick Leuven Gent Management School | Masters Business Admin |
| Ghent University | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ARGENX SE | Health Technology |
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| ITEOS THERAPEUTICS, INC. | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Health Technology |
